French VC Seventure focuses second fund on fertile microbiome field — targets €200M-plus
A few years ago, the spectacular failure of Seres Therapeutics’ seminal effort into developing a “crapsule” — a synthetic, fermented microbiome therapeutic derived by a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
